AstraZeneca Pharma Stock Screener | Share Price & Fundamental Analysis
ASTRAZEN
Pharmaceuticals
Share Price NSE
₹8889.50
▼
-13.50 (-0.15%)
Share Price BSE
₹8902.90
▲
6.40 (0.07%)
Track AstraZeneca Pharma share price live with TickJournal's free stock screener.
Analyze AstraZeneca Pharma share price history trends and compare 52-week high low
levels.
Calculate ASTRAZEN stock fair value using fundamental analysis and view live share price charts.
Determine AstraZeneca Pharma share intrinsic value and compare it with current ASTRAZEN share price.
Record your AstraZeneca Pharma trades in TickJournal's free trading journal and track your portfolio performance.
AstraZeneca Pharma Market Cap
₹22,297.50 Cr.
ASTRAZEN P/E Ratio (TTM)
109.84
EPS (TTM)
₹46.30
Dividend Yield
0.36%
Debt to Equity
0.03
ASTRAZEN 52 Week High
₹10509.50
AstraZeneca Pharma 52 Week Low
₹6698.65
Operating Margin
13.00%
Profit Margin
9.06%
ASTRAZEN Revenue (TTM)
₹2,218.00
EBITDA
₹316.00
Net Income
₹201.00
Total Assets
₹1,518.00
Total Equity
₹770.00
AstraZeneca Pharma Share Price History - Stock Screener Chart
Screen ASTRAZEN historical share price movements with interactive charts. Analyze price trends and patterns.
AstraZeneca Pharma Company Profile - Fundamental Screener
Screen AstraZeneca Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ASTRAZEN shares.
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Shilpa Divekar Nirula
ISIN
INE203A01020
Website
https://www.astrazeneca.in
AstraZeneca Pharma Balance Sheet Screener
Screen ASTRAZEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 1,518 | 1,078 | 985 | 857 | 775 | 706 | 562 | 461 | 416 | 403 |
| Current Assets | 1,342 | 933 | 836 | 706 | 619 | 542 | 405 | 321 | 252 | 267 |
| Fixed Assets | 64 | 67 | 69 | 75 | 81 | 72 | 75 | 76 | 87 | 97 |
| Liabilities | ||||||||||
| Total Liabilities | 1,518 | 1,078 | 985 | 857 | 775 | 706 | 562 | 461 | 416 | 403 |
| Current Liabilities | 45 | 9 | 12 | 13 | 15 | 15 | 2 | 7 | 2 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 770 | 712 | 589 | 511 | 456 | 364 | 301 | 247 | 223 | 156 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 765 | 707 | 584 | 506 | 451 | 359 | 296 | 242 | 218 | 151 |
AstraZeneca Pharma Income Statement Screener - Profit & Revenue Analysis
Screen AstraZeneca Pharma income statement and profit fundamentals.
Analyze ASTRAZEN quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for AstraZeneca Pharma share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,218 | 1,757 | 1,330 | 1,029 | 820 | 826 | 845 | 745 | 583 | 558 | 571 | 523 |
| Expenses | 1,901 | 1,462 | 1,111 | 838 | 719 | 678 | 711 | 657 | 525 | 507 | 547 | 529 |
| EBITDA | 316 | 295 | 219 | 191 | 101 | 148 | 134 | 88 | 59 | 51 | 23 | -6 |
| Operating Profit % | 13.00% | 15.00% | 14.00% | 16.00% | 11.00% | 17.00% | 15.00% | 10.00% | 8.00% | 7.00% | 3.00% | -2.00% |
| Depreciation | 41 | 40 | 15 | 16 | 17 | 20 | 19 | 15 | 15 | 16 | 17 | 15 |
| Interest | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 273 | 156 | 220 | 134 | 83 | 127 | 114 | 73 | 44 | 36 | 6 | -21 |
| Tax | 68 | 41 | 58 | 35 | 21 | 34 | 42 | 18 | 18 | 15 | 1 | 0 |
| Net Profit | 201 | 116 | 162 | 99 | 62 | 93 | 72 | 54 | 26 | 20 | 5 | -21 |
| EPS | 80.40 | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | -8.34 |
AstraZeneca Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ASTRAZEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 65 | 28 | 58 | 101 | 105 | 87 | 55 | 9 | 38 | 57 |
| Investing Activities | 31 | 22 | 18 | 5 | 173 | -171 | 4 | -9 | 0 | -4 |
| Financing Activities | -66 | -44 | -25 | -10 | -9 | -6 | 0 | 0 | 0 | -1 |
| Net Cash Flow | 31 | 5 | 52 | 96 | 269 | -90 | 59 | -1 | 38 | 53 |
AstraZeneca Pharma Shareholding Pattern Screener
See AstraZeneca Pharma shareholding pattern with promoter, FII, and DII holdings.
Check AstraZeneca Pharma promoter holding and ownership changes for ASTRAZEN on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FII Holding | 2.71% | 2.74% | 3.03% | 2.89% | 2.93% | 2.90% | 2.79% | 2.74% |
| DII Holding | 5.56% | 5.26% | 4.56% | 4.65% | 5.22% | 5.10% | 5.01% | 3.78% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 14.14% | 14.39% | 15.18% | 15.16% | 14.62% | 14.77% | 15.00% | 16.33% |
| Other Holding | 2.59% | 2.61% | 2.23% | 2.31% | 2.24% | 2.23% | 2.20% | 2.15% |
| Shareholder Count | 31,551 | 32,914 | 34,378 | 32,466 | 27,322 | 27,615 | 27,169 | 29,418 |
AstraZeneca Pharma Share Dividend Screener - Share Yield Analysis
Check AstraZeneca Pharma dividend history with payout and yield data.
View AstraZeneca Pharma dividend details including ex-dates and amounts for ASTRAZEN stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹32.00 | 0.36% |
| 2024-March | ₹24.00 | 0.28% |
| 2023-March | ₹16.00 | 0.30% |
| 2022-March | ₹10.00 | 0.31% |
| 2021-March | ₹2.00 | 0.08% |
| 2020-March | ₹1.00 | 0.03% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
AstraZeneca Pharma Stock Index Membership
See which indices include AstraZeneca Pharma stock.
Check ASTRAZEN index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
AstraZeneca Pharma Market Events Screener - Corporate Actions
Get AstraZeneca Pharma corporate actions including splits, bonuses, and buybacks.
Check AstraZeneca Pharma stock events that may affect ASTRAZEN share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 4.80% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -1.29% |
| 2025-08-14 | 2025-08-14 | Annual General Meeting | NA | -4.71% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -6.00% |
| 2025-07-18 | 2025-07-18 | Dividend | ₹ 32.00 /share | 18.54% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.03% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 8.88% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 3.57% |
| 2024-08-08 | 2024-08-08 | Annual General Meeting | NA | 7.26% |
| 2024-07-05 | 2024-07-05 | Dividend | ₹ 24.00 /share | 18.44% |
| 2023-07-14 | 2023-07-14 | Dividend | ₹ 16.00 /share | 15.81% |
| 2022-08-08 | 2022-08-08 | Annual General Meeting | NA | 3.23% |
| 2022-07-07 | 2022-07-08 | Dividend | ₹ 8.00 /share | 10.01% |
| 2021-08-18 | 2021-08-20 | Dividend | ₹ 2.00 /share | -8.95% |
AstraZeneca Pharma Competitors Screener - Peer Comparison
Screen ASTRAZEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 407,287 | 37.56 | 54,729 | 9.71% | 10,980 | 52.49 |
| Divis Laboratories | 163,754 | 66.27 | 9,712 | 18.67% | 2,191 | 48.87 |
| Torrent Pharmaceuticals | 138,018 | 64.55 | 11,539 | 6.99% | 1,911 | 59.36 |
| Cipla | 107,555 | 23.69 | 28,410 | 7.12% | 5,291 | 35.86 |
| Dr Reddys Laboratories | 105,839 | 19.26 | 33,741 | 16.73% | 5,725 | 58.24 |
| Lupin | 100,464 | 23.23 | 22,910 | 13.74% | 3,306 | 56.93 |
| Zydus Life Science | 91,034 | 18.43 | 23,511 | 18.55% | 4,615 | 51.32 |
| Mankind Pharma | 85,058 | 47.59 | 12,744 | 20.90% | 2,007 | 42.02 |
| Aurobindo Pharma | 66,537 | 19.29 | 32,346 | 9.43% | 3,484 | 45.13 |
| Alkem Laboratories | 64,595 | 29.06 | 13,458 | 3.70% | 2,216 | 36.02 |
AstraZeneca Pharma Company Announcements - News Screener
Screen ASTRAZEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-02-19 | Outcome Of The Board Meeting Held On Wednesday February 11 2026 | View |
| 2026-02-19 | Appointment of Company Secretary and Compliance Officer | View |
| 2026-02-18 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2026-02-02 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Disclosure Of ESG Rating | View |
| 2026-01-31 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2026-01-31 | Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results Of The Company For The Quarter Ended December 31 2025. | View |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Resignation of Director | View |
| 2026-01-16 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2026-01-16 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2026-01-16 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2026-01-09 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Senior Management Personnel | View |
| 2025-12-17 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 | View |
| 2025-12-15 | Closure of Trading Window | View |
| 2025-12-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-12-08 | Determination Of Materiality - Details Of Key Managerial Personnel | View |
| 2025-11-27 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-18 | Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-17 | Intimation About Second Brand Partnership Between Astrazeneca Pharma India Limited ("Company") And Sun Pharmaceuticals Industries Limited For Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5 G | View |
| 2025-11-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |